Sentences with phrase «for zinc finger»

A conserved role for the zinc finger polyadenosine RNA binding protein, ZC3H14, in control of poly (A) tail length.

Because Huntington's disease is caused by a single faulty gene, it's a good candidate for zinc finger drug research.

Not exact matches

Announced a worldwide collaboration with Sangamo Therapeutics, Inc. (Sangamo) using Sangamo's zinc finger nuclease technology platform for the development of next - generation ex vivo cell therapies in oncology.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Osmosis has re-defined the standard for DNA repair technology with their parented Zinc Finger Technology.

However, in the presentations, speakers for both teams said that two stretches of the gene code for so - called zinc fingers — protein structures that insert themselves into the grooves of DNA — suggesting that the encoded protein probably turns other genes on and off.

In that case, six patients suspended antiretroviral therapy for 12 weeks after infusion with zinc finger nuclease — altered CD4 cells.

Its competitors — designer proteins called zinc finger nucleases and TALENs — also precisely alter chosen DNA sequences, and several companies are already exploiting them for therapeutic purposes in clinical trials.

In clinical trials already underway, for example, researchers have used an older gene - editing technique, enzymes call zinc finger nucleases, in immune cells to deactivate the gene for CCR5, a surface protein that HIV latches onto in order to infect cells.

In the new study involving mice, published in the journal Molecular Neurodegeneration, the injection of zinc finger repressed the mutant copies of the gene for at least six months.

In 2009, for example, Sangamo Therapeutics in Richmond, California, began using zinc finger nucleases to modify genes in immune cells from HIV - infected people, hoping to make the cells resistant to the virus.

In 2009, researchers at Dow AgroSciences in Indianapolis, Indiana, and Sangamo BioSciences in Richmond, California, announced that they had used enzymes called zinc - finger nucleases to insert a gene for herbicide resistance at a specific site in the maize genome (V. K. Shukla et al..

What's more, say the researchers, the cancer - causing effects of off - target deletions mistakenly created by the V (D) J enzyme need to be considered in designing site - specific enzymes for genome modification such as zinc - finger nucleases, TALENS, or CRISPRs.

In it, they sound the alarm about new genome - editing techniques known as CRISPR and zinc - finger nucleases that make it much easier for scientists to delete, add, or change specific genes.

Asuri et al, for example, used zinc fingers to increase the efficiency of AAV mediated genome editing in human ESCs and iPSCs from ~ 0.2 % to ~ 1.5 %.

For DNA cleavage to occur, two zinc finger proteins must bind, each to specific, adjoining sequences in the CCR5 gene, leading to FokI dimerization and subsequent DNA cleavage resulting in a double strand break [24]--[26].

If what you've read here about zinc finger technology reminds you of «gene silencing» or «huntingtin - lowering» methods for treating Huntington's disease, give yourself a gold star.

A similar approach, but using a different technology (zinc finger nucleases), was reported for Huntington's disease in 2012.

When the virus meets a suitable cell, it injects its DNA cargo into the cell, turning the cell into a factory for making the zinc - finger drug!

So one zinc finger could stick to the sequence «ATG», while another might go for «CAG».

We identified the protein Organelle Zinc Finger Protein 1 (OZ1) as required for editing of 14 targets in Arabidopsis.

When zinc hooks up with a gene - controlling protein, it forms «zinc finger proteins» - so called because they can poke into the tight groove between the two strands of DNA and touch the sequence they're made for.

The variety of new tools available for genetic manipulation now include lentiviral - based gene delivery, and gene editing using CRISPR / Cas9, zinc finger nucleases (ZFNs) or transcription activator - like effector nucleases (TALENs).

Both technologies have been around for longer than CRISPR has, with zinc - finger - based editing being in the works for more than two decades.

Eventually, the team of Dow and Sangamo scientists showed that it could engineer zinc finger nucleases that gave a two - for - one deal.

Zinc finger technology is one of the hottest areas now in everything from gene therapy for HIV to increasing crop yield, to therapeutic protein production, to the great hope for stem cell therapy.